Back to Authors

Karim, Mohammed

Mayo Clinic

Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN 55905, USA.

Citations 2

Intraoperative Surgeon Assessment of Bone
Bernatz, James T. , Skjaerlund, Jonathan, Mikula, Anthony L. , Johnson, Sarah E. , Bydon, Mohamad , Fogelson, Jeremy L. , Elder, Benjamin D. , Sebastian, Arjun S. , Freedman, Brett A. , Goh, Brian C, Skjaerlund, Jonathan D, Fogelson, Jeremy, Elder, Benjamin, Huddleston, Paul, Karim, Mohammed, Sebastian, Arjun, Goh, Brian Chun Kim , Huddleston, P.M. , Karim, Mohammed, Nassr, Ahmad

Spine | October 19, 2023 | Volume: 49 | Issue: 16 | Pages: 1125-1129

10.1097/brs.0000000000004854 Get It

Study design. Retrospective observational study of consecutive patients. Objective. The purpose of the study is to determine if a surgeon’s qualitative assessment of bone intraoperatively correlates with radiologic parameters of bone strength. Summary of Background Data. Preoperative radiologic assessment of bone can include modalities such as computed tomography (CT) Hounsfield units (HUs), dual-energy x-ray absorptiometry (DXA) bone mineral density with trabecular bone score (TBS) and magnetic resonance imaging vertebral bone quality (VBQ). Quantitative analysis of bone with screw insertional torque and pull-out strength measurement has been performed in cadaveric models and has been correlated to these radiologic parameters. However, these quantitative measurements are not routinely available for use in surgery. Surgeons anecdotally judge bone strength, but the fidelity of the intraoperative judgment has not been investigated. Methods. All adult patients undergoing instrumented posterior thoracolumbar spine fusion by one of seven surgeons at a single center over a 3-month period were included. Surgeons evaluated the strength of bone based on intraoperative feedback and graded each patient’s bone on a 5-point Likert scale. Two independent reviewers measured preoperative CT HUs and magnetic resonance imaging VBQ. Bone mineral density, lowest T-score, and TBS were extracted from DXA within 2 years of surgery. Results. Eighty-nine patients were enrolled and 16, 28, 31, 13, and 1 patients had Likert grade 1 (strongest bone), 2, 3, 4, and 5 (weakest bone), respectively. The surgeon assessment of bone correlated with VBQ (τ=0.15, P=0.07), CT HU (τ=−0.31, P<0.01), lowest DXA T-score (τ=−0.47, P<0.01), and TBS (τ=−0.23, P=0.06). Conclusion. Spine surgeons’ qualitative intraoperative assessment of bone correlates with preoperative radiologic parameters, particularly in posterior thoracolumbar surgeries. This information is valuable to surgeons as this supports the idea that decisions based on feel in surgery have a statistical foundation.
Pragmatic, Prospective Comparative Effectiveness Trial of Carbon Ion Therapy, Surgery, and Proton Therapy for the Management of Pelvic Sarcomas (Soft Tissue/Bone) Involving the Bone: The PROSPER Study Rationale and Design
Petersen, Ivy A. , Imai, Reiko , Hug, Eugen B., Fiore, Maria Rosaria , Fossati, Piero , Yamada, Shigeru , Orlandi, Ester , Zhang, Qing, Bao, Cihang , Seidensaal, Katharina , May, Byron C. , Harrell, Anna , Houdek, Matthew T. , Vallow, Laura A., Rose, Peter S. , Haddock, Michael G. , Ashman, Jonathan B. , Goulding, Krista , Attia, Steven , Krishnan, Sunil , Mahajan, Anita , Foote, Robert L. , Keole, Sameer R., Beltran, Chris , Welch, Eric M., Wilke, Benjamin K. , Imai, Reiko , Yamada, Shigeru , Zhang, Qing , May, Byron C , Harrell, Anna C , Houdek, Matthew T , Goulding, Krista A., Krishnan, Sunil , Foote, Robert , Karim, Mohammed, Ahmed, Safia K. , Beltran, Chris J , Hoppe, Bradford S. , DeWees, T.A. , Debus, Jürgen , Laack, Nadia N. , Karim, Mohammed

Cancers | March 8, 2023 | Volume: 15 | Issue: 6 | Pages: 1660

10.3390/cancers15061660 Get It

Surgical treatment of pelvic sarcoma involving the bone is the standard of care but is associated with several sequelae and reduced functional quality of life (QOL). Treatment with photon and proton radiotherapy is associated with relapse. Carbon ion radiotherapy (CIRT) may reduce both relapse rates and treatment sequelae. The PROSPER study is a tricontinental, nonrandomized, prospective, three-arm, pragmatic trial evaluating treatments of pelvic sarcoma involving the bone. Patients aged at least 15 years are eligible for inclusion. Participants must have an Eastern Cooperative Oncology Group Performance Status score of two or less, newly diagnosed disease, and histopathologic confirmation of pelvic chordoma, chondrosarcoma, osteosarcoma, Ewing sarcoma with bone involvement, rhabdomyosarcoma (RMS) with bone involvement, or non-RMS soft tissue sarcoma with bone involvement. Treatment arms include (1) CIRT (n = 30) delivered in Europe and Asia, (2) surgical treatment with or without adjuvant radiotherapy (n = 30), and (3) proton therapy (n = 30). Arms two and three will be conducted at Mayo Clinic campuses in Arizona, Florida, and Minnesota. The primary end point is to compare the 1-year change in functional QOL between CIRT and surgical treatment. Additional comparisons among the three arms will be made between treatment sequelae, local control, and other QOL measures.